Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Smallpox vaccine, LISTER strain, from chick embryo cells · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Smallpox vaccine, LISTER strain, from chick embryo cells | BIOLOGICAL | - |
Inclusion Criteria: * Aged 18 to 25 years on the day of screening * Informed consent form signed * Able to attend all scheduled visits and to comply with all trial procedures * For a woman, inability to bear a child or negative serum pregnancy test performed at screening (Visit 01) * Subject entitl...
It is a vaccine being developed for protection against smallpox, a serious infectious disease caused by the variola virus. It is based on the LISTER strain of vaccinia virus grown in chick embryo cells. It is intended for use in healthy adults and is currently in clinical development.
The vaccine is being developed by Sanofi, which trades under the ticker SNY. Sanofi is a global pharmaceutical company. The vaccine is in Phase 2 clinical development for smallpox.
It is in Phase 2 clinical development. One Phase 2 trial has been completed. The vaccine is investigational and has not been approved by the FDA. It is being studied for safety and its ability to produce a take response in healthy young adults.
It has been studied in one completed Phase 2 trial, NCT00258947, titled Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults. The trial enrolled 230 healthy volunteers aged 18 years and older in France. It was randomized and double-blind.
It is a vaccine based on the LISTER strain of vaccinia virus, which is grown in chick embryo cells. Vaccinia virus is related to variola virus, the cause of smallpox, and vaccination induces an immune response that provides protection against smallpox. The vaccine is designed to produce a take response at the vaccination site.